Current and future pharmacotherapy options for drug-resistant epilepsy

Area of Science:

• Neurology
• Pharmacology
• Epilepsy Research

Background:

• Epilepsy affects over 70 million people globally, with a significant portion experiencing drug-resistant forms.
• Drug-resistant epilepsy presents a substantial challenge in neurological patient care.
• Current treatment paradigms struggle to adequately manage refractory epilepsy cases.

Approach:

• Comprehensive review of existing and investigational pharmacotherapy options for epilepsy.
• Analysis of drugs in preclinical and clinical development stages (Phase II, Phase III).
• Examination of novel molecular targets and therapeutic strategies for epilepsy.

Key Points:

• Current options for drug-resistant epilepsy include perampanel, brivaracetam, cenobamate, cannabidiol, fenfluramine, and ganaxolone for specific syndromes.
• Advanced clinical development (Phase III) includes padsevonil and carisbamate for adult focal epilepsies.
• Emerging treatments target specific epilepsy syndromes like KCNQ2-DEE, Lennox-Gastaut Syndrome, and Tuberous Sclerosis Complex.
• Preclinical research focuses on novel targets such as glycolysis inhibition, neuroinflammation, and sodium channel modulation.

Conclusions:

• Several new pharmacotherapies are approved or in late-stage development for drug-resistant epilepsy.
• Future epilepsy treatment will likely involve targeted therapies for specific syndromes and novel molecular pathways.
• Continued research in preclinical models is crucial for identifying and validating future drug targets.